Pacira Pharmaceuticals, Inc. to Present at the 34th Annual

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference

PARSIPPANY, N.J., Dec. 28, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX ) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 34 th Annual J.P. Morgan Healthcare Conference at 4 p.m. PT (7 p.m. ET) on Monday, January 11, 2016, in San Francisco. Mr. Stack is expected to present an overview of the company.

A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com . A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.

About Pacira                                                                           

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX ) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com .

Company Contact: Pacira Pharmaceuticals, Inc. Jessica Cho, (973) 254-3574

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Solis Agrosciences Gains Series A Funding to Drive Growth Forward

Updated Category News Views 272

Solis Agrosciences Gains Series A Funding to Drive Growth Forward Solis Agrosciences, a prominent name in the Agtech sector, has announced a significant milestone in its journey of innovation and growth. The company has successfully secured Series A funding from Cultivation Capital, an investment that promises to amplify its business operations and expand its array of...

Continue Reading
Blink Charging: Milestone Achievements and Future Outlook

Updated Category News Views 283

Update on Blink Charging and Its Stock Performance Blink Charging Co. (NASDAQ: BLNK) shares saw an upward trend recently, as the company proudly announced it surpassed 100,000 electric vehicle (EV) chargers sold, deployed, or contracted globally. This significant accomplishment highlights Blink's growth in the EV infrastructure sector. The company's success can be...

Continue Reading
Vanguard Unveils Innovative Active Equity ETF Range

Updated Category News Views 228

Vanguard Launches New Active Equity ETFs Vanguard has recently introduced three active equity ETFs aimed at enhancing investor portfolio options. The newly launched funds are the Vanguard Wellington U.S. Value Active ETF (VUSV), Vanguard Wellington U.S. Growth Active ETF (VUSG), and Vanguard Wellington Dividend Growth Active ETF (VDIG), each managed by the esteemed...

Continue Reading
New COVID-19 Vaccine by Pfizer and BioNTech Shows Promise

Updated Category News Views 244

Revamped Approach to COVID-19 Vaccination In a noteworthy advancement in the fight against the COVID-19 pandemic, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) are set to introduce an LP.8.1-adapted monovalent COVID-19 vaccine following a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)....

Continue Reading
Gold's Steady Climb Amid Geopolitical Tensions and Economic Shifts

Updated Category News Views 210

Gold Rises for Third Consecutive Session Gold (XAU/USD) has shown a steady increase of over 0.32%, reflecting a notable rise in safe-haven demand driven by global trade tensions. Investors remain concerned about the stability of global supply chains, making gold a popular choice during times of uncertainty. The yellow metal typically shines as a safe-haven asset when...

Continue Reading